

World Health Organization Regional Office for the Eastern Mediterranean

# Guidelines on minimum requirements for the registration of herbal medicinal products in the Eastern Mediterranean Region



World Health Organization
Regional Office for the Eastern Mediterranean
Cairo
2006

#### © World Health Organization 2006

#### All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

Publications of the World Health Organization can be obtained from Distribution and Sales, World Health Organization, Regional Office for the Eastern Mediterranean, PO Box 7608, Nasr City, Cairo 11371, Egypt (tel: +202 670 2535, fax: +202 670 2492; email: DSA@emro.who.int). Requests for permission to reproduce WHO EMRO publications, in part or in whole, or to translate them – whether for sale or for noncommercial distribution – should be addressed to the Regional Adviser, Health and Biomedical Information, at the above address (fax: +202 276 5400; email HBI@emro.who.int).

Cover design by Ahmed Salah Mostafa Printed by Grace Team, Cairo

Document WHO-EM/EDB/048/E/03.06/1000

### **Contents**

Acknowledgements	. 4
Introduction	.5
Guidelines on minimum requirements for the registration of herbal	
medicinal products	.7
Categorization of herbal medicines	. 7
Requirements for safety of "new herbal medicines"	. 8
Requirements for safety of traditional herbal medicines	.8
Minimum requirements for efficacy of herbal medicinal products	. 9
Quality control of herbal medicinal products1	10
Pharmacovigilance of herbal medicinal products1	14
Control of advertisements of herbal medicinal products1	6
Annex 1. List of participants at the first workshop1	17
Annex 2. List of participants at the second workshop2	21
Annex 3. Work of the Regional Office in the area of traditional, alternative and	
complementary medicine2	

# **Acknowledgements**

WHO acknowledges with special thanks the Grand Duchy of Luxembourg for its financial contribution, host countries of the first and second workshop on regulation of herbal medicine, namely the Governments of the Islamic Republic of Iran and United Arab Emirates, and distinguished participants, who provided comments, presentations and valuable advice during the preparation of these guidelines. WHO also acknowledges with gratitude the contributions of experts from the Federal Institute for Drugs and Medical Devices in Germany, the State Food and Drug Administration of China, and the Natural Health Products Directorate of Canada.

## Introduction

Global sales of herbal medicines have increased rapidly during the past decade. The Secretariat of the Convention on Biological Diversity estimated the global herbal medicines market at US\$ 60 billion in 2000. In Japan, the herbal medicines market more than doubled between 1991 and 2000. In the United States, the market expanded from US\$ 1.6 billion in 1994 to US\$ 5.4 billion in 2000.

Use of herbal medicines has also increased steadily in countries of the WHO Eastern Mediterranean Region. In some countries, for example the Islamic Republic of Iran, herbal medicines are produced locally and a large population depends on them for primary health care. In other countries, such as the United Arab Emirates, the majority of herbal products are obtained from the United States, Europe or Asia. A major problem in the evaluation of imported herbal products is that they often contain more than 10 plants, and it is very difficult to conduct testing and quality control. Another problem is that classification categories for herbal products vary from country to country; some categories include functional foods, dietary supplements and traditional medicines.

Overall, there is a lack of cooperation and information sharing regarding market control between the ministries of health of different countries in the Region. Important data related to safety, efficacy and quality control are often either insufficient or not available. In most countries, either no safety monitoring system exists or the existing system excludes herbal medicines.

Governments need to establish their national regulations on the control of imported herbal medicines through sharing experiences and harmonizing standards on safety and quality control across national boundaries. Eastern Mediterranean Drug Regulatory Authorities Conferences in 1999 and 2001 provided general guidance to drug regulatory authorities in the development and implementation of preliminary regulatory systems for herbal medicines. Specific guidance is needed, however, to meet the needs of countries that are primarily producers and those that are primarily importers of herbal medicines. In 2002, the Forty-ninth Session of the WHO Regional Committee for the Eastern Mediterranean adopted a resolution on traditional medicine (EM/RC49/R.9) in which it requested the Regional Director to take necessary action to develop guidelines for the preparation of national policies and regulations on

预览已结束,完整报告链接和二维码如下

https://www.yunbaogao.cn/report/index/report?reportId=5\_29762

The state of many